Neuropsychobiology

Original Paper

Serotonin 7 Receptor Variants Are Not Associated with Response to Second-Generation Antipsychotics in Japanese Schizophrenia Patients

Takekita Y.a, b · Fabbri C.a · Kato M.b · Nonen S.c · Sakai S.b · Sunada N.b · Koshikawa Y.b · Wakeno M.b · Okugawa G.b · Kinoshita T.b · Serretti A.a

Author affiliations

aDepartment of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy; bDepartment of Neuropsychiatry, Kansai Medical University, Osaka, and cDepartment of Pharmacy, Hyogo University of Health Sciences, Kobe, Japan

Keywords: Second-generation antipsychoticsPolymorphismSchizophreniaHTR7PharmacogeneticsEfficacy5-HTAntipsychotics

Related Articles for ""
Neuropsychobiology 2015;72:118-125
https://doi.org/10.1159/000441629

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: February 12, 2015
Accepted: October 05, 2015
Published online: November 27, 2015
Issue release date: December 2015

Number of Print Pages: 8
Number of Figures: 1
Number of Tables: 3

ISSN: 0302-282X (Print)
eISSN: 1423-0224 (Online)

For additional information: https://www.karger.com/NPS

Abstract

Background: Individual differences in serotonin 7 receptor (5-HT7R) may result in variable response to antipsychotics with 5-HT7R antagonism. This study investigated the relationship between single nucleotide polymorphisms (SNPs) in the 5-HT7R gene (HTR7) and the efficacy of second-generation antipsychotic drugs with a high affinity for this receptor in Japanese schizophrenia. Methods: Perospirone or aripiprazole was administered to 100 patients with schizophrenia in a randomized controlled study. All patients were genotyped for three candidate SNPs (rs12412496, rs7916403, and rs1935349). Patient improvement on the Positive and Negative Syndrome Scale (PANSS) total score at 12 weeks was assessed as the primary outcome. PANSS 5-factor scores were investigated as the secondary outcome. Results: Improvement on the PANSS total score and genetic polymorphisms showed no correlation. The rs12412496-rs7916403-rs1935349 A-T-A haplotype was correlated with worse improvement in the cognition score (haplotype frequency: 0.285, p = 0.046, permuted p = 0.043). Conclusion: Our results show that HTR7 variants are not related to the overall improvement in schizophrenia symptoms.

© 2015 S. Karger AG, Basel



Related Articles:

References

  1. Bard JA, Zgombick J, Adham N, Vaysse P, Branchek TA, Weinshank RL: Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase. J Biol Chem 1993;268:23422-23426.
    External Resources
  2. Lovenberg TW, Baron BM, de Lecea L, Miller JD, Prosser RA, Rea MA, Foye PE, Racke M, Slone AL, Siegel BW, et al: A novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms. Neuron 1993;11:449-458.
    External Resources
  3. Ruat M, Traiffort E, Leurs R, Tardivel-Lacombe J, Diaz J, Arrang JM, Schwartz JC: Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating camp formation. Proc Natl Acad Sci USA 1993;90:8547-8551.
    External Resources
  4. Leopoldo M, Lacivita E, Berardi F, Perrone R, Hedlund PB: Serotonin 5-HT7 receptor agents: structure-activity relationships and potential therapeutic applications in central nervous system disorders. Pharmacol Ther 2011;129:120-148.
    External Resources
  5. Neumaier JF, Sexton TJ, Yracheta J, Diaz AM, Brownfield M: Localization of 5-HT(7) receptors in rat brain by immunocytochemistry, in situ hybridization, and agonist stimulated cFos expression. J Chem Neuroanat 2001;21:63-73.
    External Resources
  6. Muneoka KT, Takigawa M: 5-hydroxytryptamine7 (5-HT7) receptor immunoreactivity-positive ‘stigmoid body'-like structure in developing rat brains. Int J Dev Neurosci 2003;21:133-143.
    External Resources
  7. Bonaventure P, Nepomuceno D, Hein L, Sutcliffe JG, Lovenberg T, Hedlund PB: Radioligand binding analysis of knockout mice reveals 5-hydroxytryptamine(7) receptor distribution and uncovers 8-hydroxy-2-(di-n-propylamino)tetralin interaction with alpha(2) adrenergic receptors. Neuroscience 2004;124:901-911.
    External Resources
  8. Varnas K, Thomas DR, Tupala E, Tiihonen J, Hall H: Distribution of 5-HT7 receptors in the human brain: a preliminary autoradiographic study using [3H]SB-269970. Neurosci Lett 2004;367:313-316.
    External Resources
  9. Thomas DR, Hagan JJ: 5-HT7 receptors. Curr Drug Targets CNS Neurol Disord 2004;3:81-90.
    External Resources
  10. Ehlen JC, Grossman GH, Glass JD: In vivo resetting of the hamster circadian clock by 5-HT7 receptors in the suprachiasmatic nucleus. J Neurosci 2001;21:5351-5357.
    External Resources
  11. Glass JD, Grossman GH, Farnbauch L, DiNardo L: Midbrain raphe modulation of nonphotic circadian clock resetting and 5-HT release in the mammalian suprachiasmatic nucleus. J Neurosci 2003;23:7451-7460.
    External Resources
  12. Thomas DR, Melotto S, Massagrande M, Gribble AD, Jeffrey P, Stevens AJ, Deeks NJ, Eddershaw PJ, Fenwick SH, Riley G, Stean T, Scott CM, Hill MJ, Middlemiss DN, Hagan JJ, Price GW, Forbes IT: SB-656104-A, a novel selective 5-HT7 receptor antagonist, modulates REM sleep in rats. Br J Pharmacol 2003;139:705-714.
    External Resources
  13. Hedlund PB, Huitron-Resendiz S, Henriksen SJ, Sutcliffe JG: 5-HT7 receptor inhibition and inactivation induce antidepressantlike behavior and sleep pattern. Biol Psychiatry 2005;58:831-837.
    External Resources
  14. Hedlund PB, Danielson PE, Thomas EA, Slanina K, Carson MJ, Sutcliffe JG: No hypothermic response to serotonin in 5-HT7 receptor knockout mice. Proc Natl Acad Sci USA 2003;100:1375-1380.
    External Resources
  15. Beique JC, Campbell B, Perring P, Hamblin MW, Walker P, Mladenovic L, Andrade R: Serotonergic regulation of membrane potential in developing rat prefrontal cortex: coordinated expression of 5-hydroxytryptamine (5-HT)1A, 5-HT2A, and 5-HT7 receptors. J Neurosci 2004;24:4807-4817.
    External Resources
  16. Laplante P, Diorio J, Meaney MJ: Serotonin regulates hippocampal glucocorticoid receptor expression via a 5-HT7 receptor. Brain Res Dev Brain Res 2002;139:199-203.
    External Resources
  17. Weaver IC, La Plante P, Weaver S, Parent A, Sharma S, Diorio J, Chapman KE, Seckl JR, Szyf M, Meaney MJ: Early environmental regulation of hippocampal glucocorticoid receptor gene expression: characterization of intracellular mediators and potential genomic target sites. Mol Cell Endocrinol 2001;185:205-218.
    External Resources
  18. Bonaventure P, Kelly L, Aluisio L, Shelton J, Lord B, Galici R, Miller K, Atack J, Lovenberg TW, Dugovic C: Selective blockade of 5-hydroxytryptamine (5-HT)7 receptors enhances 5-HT transmission, antidepressant-like behavior, and rapid eye movement sleep suppression induced by citalopram in rodents. J Pharmacol Exp Ther 2007;321:690-698.
    External Resources
  19. Wesolowska A, Tatarczynska E, Nikiforuk A, Chojnacka-Wojcik E: Enhancement of the anti-immobility action of antidepressants by a selective 5-HT7 receptor antagonist in the forced swimming test in mice. Eur J Pharmacol 2007;555:43-47.
    External Resources
  20. Wesolowska A, Nikiforuk A, Stachowicz K, Tatarczynska E: Effect of the selective 5-HT7 receptor antagonist SB 269970 in animal models of anxiety and depression. Neuropharmacology 2006;51:578-586.
    External Resources
  21. Roberts AJ, Krucker T, Levy CL, Slanina KA, Sutcliffe JG, Hedlund PB: Mice lacking 5-HT receptors show specific impairments in contextual learning. Eur J Neurosci 2004;19:1913-1922.
    External Resources
  22. Meneses A: Effects of the 5-HT7 receptor antagonists SB-269970 and DR 4004 in autoshaping Pavlovian/instrumental learning task. Behav Brain Res 2004;155:275-282.
    External Resources
  23. McLean SL, Woolley ML, Thomas D, Neill JC: Role of 5-HT receptor mechanisms in sub-chronic PCP-induced reversal learning deficits in the rat. Psychopharmacology (Berl) 2009;206:403-414.
    External Resources
  24. Horiguchi M, Huang M, Meltzer HY: The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats. J Pharmacol Exp Ther 2011;338:605-614.
    External Resources
  25. Waters KA, Stean TO, Hammond B, Virley DJ, Upton N, Kew JN, Hussain I: Effects of the selective 5-HT(7) receptor antagonist SB-269970 in animal models of psychosis and cognition. Behav Brain Res 2012;228:211-218.
    External Resources
  26. Nikiforuk A, Kos T, Fijal K, Holuj M, Rafa D, Popik P: Effects of the selective 5-HT7 receptor antagonist SB-269970 and amisulpride on ketamine-induced schizophrenia-like deficits in rats. PloS One 2013;8:e66695.
    External Resources
  27. East SZ, Burnet PW, Kerwin RW, Harrison PJ: An RT-PCR study of 5-HT(6) and 5-HT(7) receptor mRNAs in the hippocampal formation and prefrontal cortex in schizophrenia. Schizophr Res 2002;57:15-26.
    External Resources
  28. Fallin MD, Lasseter VK, Wolyniec PS, McGrath JA, Nestadt G, Valle D, Liang KY, Pulver AE: Genomewide linkage scan for schizophrenia susceptibility loci among Ashkenazi Jewish families shows evidence of linkage on chromosome 10q22. Am J Hum Genet 2003;73:601-611.
    External Resources
  29. Mowry BJ, Ewen KR, Nancarrow DJ, Lennon DP, Nertney DA, Jones HL, O'Brien MS, Thornley CE, Walters MK, Crowe RR, Silverman JM, Endicott J, Sharpe L, Hayward NK, Gladis MM, Foote SJ, Levinson DF: Second stage of a genome scan of schizophrenia: study of five positive regions in an expanded sample. Am J Med Genet 2000;96:864-869.
    External Resources
  30. Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL: Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacol 2009;205:119-128.
    External Resources
  31. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr, Shen Y, Meltzer HY, Sibley DR: Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 1994;268:1403-1410.
    External Resources
  32. Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R, Matsumoto K, Nishikawa H, Ueda Y, Toma S, Oki H, Tanno N, Saji I, Ito A, Ohno Y, Nakamura M: Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther 2010;334:171-181.
    External Resources
  33. Murasaki M, Nishikawa H, Ishibashi T: Dopamine-serotonin antagonist: receptor binding profile of a novel antipsychotic blonanserin. Jpn Clin Psychopharmacol 2008;11:845-854.
  34. Nikiforuk A, Popik P: Amisulpride promotes cognitive flexibility in rats: the role of 5-HT7 receptors. Behav Brain Res 2013;248:136-140.
    External Resources
  35. Brennan MD: Pharmacogenetics of second-generation antipsychotics. Pharmacogenomics 2014;15:869-884.
    External Resources
  36. The Nucleotide Database (online). Bethesda, National Center for Biotechnology Information, 1982. http://www.ncbi.nlm.nih.gov/nucleotide/.
  37. Matthys A, Haegeman G, Van Craenenbroeck K, Vanhoenacker P: Role of the 5-HT7 receptor in the central nervous system: from current status to future perspectives. Mol Neurobiol 2011;43:228-253.
    External Resources
  38. Ikeda M, Iwata N, Kitajima T, Suzuki T, Yamanouchi Y, Kinoshita Y, Ozaki N: Positive association of the serotonin 5-HT7 receptor gene with schizophrenia in a Japanese population. Neuropsychopharmacology 2006;31:866-871.
    External Resources
  39. Ikeda M, Yamanouchi Y, Kinoshita Y, Kitajima T, Yoshimura R, Hashimoto S, O'Donovan MC, Nakamura J, Ozaki N, Iwata N: Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. Pharmacogenomics 2008;9:1437-1443.
    External Resources
  40. Wei Z, Wang L, Xuan J, Che R, Du J, Qin S, Xing Y, Gu B, Yang L, Li H, Li J, Feng G, He L, Xing Q: Association analysis of serotonin receptor 7 gene (HTR7) and risperidone response in Chinese schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:547-551.
    External Resources
  41. Lavedan C, Licamele L, Volpi S, Hamilton J, Heaton C, Mack K, Lannan R, Thompson A, Wolfgang CD, Polymeropoulos MH: Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study. Mol Psychiatry 2009;14:804-819.
    External Resources
  42. Takekita Y, Kato M, Wakeno M, Sakai S, Suwa A, Nishida K, Okugawa G, Kinoshita T: A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients. Prog Neuropsychopharmacology Biol Psychiatry 2013;40:110-114.
    External Resources
  43. Inagaki A, Inada T: Dose equivalence of psychotropic drugs. Part XVII. Dose equivalence of novel antipsychotics: aripiprazole. Jpn J Clin Psychopharmacol 2006;9:249-258.
  44. Lindenmayer JP, Grochowski S, Hyman RB: Five factor model of schizophrenia: replication across samples. Schizophr Res 1995;14:229-234.
    External Resources
  45. Citrome L, Meng X, Hochfeld M: Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis. Schizophr Res 2011;131:75-81.
    External Resources
  46. Haploview (computer program). Cambridge, Daly Lab at the Broad Institute, 2008.
  47. Kim JH, Park BL, Cheong HS, Bae JS, Kim LH, Kim JW, Lee BC, Seo CH, Kang TC, Park SH, Choi IG, Shin HD: Association between HTR7 genetic polymorphisms and alcohol dependence, using the alcohol use disorders identification test (AUDIT). Alcohol Clin Exp Res 2014;38:2354-2361.
    External Resources
  48. Zlojutro M, Manz N, Rangaswamy M, Xuei X, Flury-Wetherill L, Koller D, Bierut LJ, Goate A, Hesselbrock V, Kuperman S, Nurnberger J Jr, Rice JP, Schuckit MA, Foroud T, Edenberg HJ, Porjesz B, Almasy L: Genome-wide association study of theta band event-related oscillations identifies serotonin receptor gene HTR7 influencing risk of alcohol dependence. Am J Med Genet B Neuropsychiatr Genet 2011;156B:44-58.
    External Resources
  49. R: A Language and Environment for Statistical Computing (computer program). Vienna, R Development Core Team, 2014.
  50. G*POWER (computer program). Düsseldorf, Heinrich-Heine-Universität, 2013.
  51. Cohen J: A power primer. Psychol Bull 1992;112:155-159.
    External Resources
  52. Cohen J: Statistical Power Analysis for the Behavioral Sciences, ed 2. Mahwah, Lawrence Erlbaum Associates, 1988.
  53. Robinson DG, Woerner MG, Alvir JM, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Bilder R, Goldman R, Lieberman JA: Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999;156:544-549.
    External Resources
  54. Jager M, Riedel M, Messer T, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Huff W, Heuser I, Kühn KU, Lemke MR, Ruther E, Buchkremer G, Gastpar M, Bottlender R, Strauss A, Möller HJ: Psychopathological characteristics and treatment response of first episode compared with multiple episode schizophrenic disorders. Eur Arch Psychiatry Clin Neurosci 2007;257:47-53.
    External Resources
  55. Emsley R, Oosthuizen P, Koen L, Niehaus D, Martinez L: Comparison of treatment response in second-episode versus first-episode schizophrenia. J Clin Psychopharmacol 2013;33:80-83.
    External Resources
  56. Washida K, Takeda T, Habara T, Sato S, Oka T, Tanaka M, Yoshimura Y, Aoki S: Efficacy of second-generation antipsychotics in patients at ultra-high risk and those with first-episode or multi-episode schizophrenia. Neuropsychiatr Dis Treat 2013;9:861-868.
    External Resources
  57. Hedlund PB: The 5-HT7 receptor and disorders of the nervous system: an overview. Psychopharmacology 2009;206:345-354.
    External Resources
  58. Takekita Y, Fabbri C, Kato M, Nonen S, Sakai S, Sunada N, Koshikawa Y, Wakeno M, Okugawa G, Kinoshita T, Serretti A: HTR1A gene polymorphisms and 5-HT1A receptor partial agonist antipsychotics efficacy in schizophrenia. J Clin Psychopharmacol 2015;35:220-227.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: February 12, 2015
Accepted: October 05, 2015
Published online: November 27, 2015
Issue release date: December 2015

Number of Print Pages: 8
Number of Figures: 1
Number of Tables: 3

ISSN: 0302-282X (Print)
eISSN: 1423-0224 (Online)

For additional information: https://www.karger.com/NPS

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2015, Vol.72, No. 2

December 2015

Article

Recommend This
TOP